Event
XCath secures $30M Series C to advance neuro-endovascular surgical robotics
Key points
- XCath announced a $30M Series C to support development and future commercialization of its endovascular surgical robot.
- The round was co-led by Crescent Enterprises and Dr. Fred Moll, chairman of XCath's board.
- The financing brought total capital raised since the company's 2017 founding to $92M.
Company context
Develops neuro-endovascular surgical robotics and steerable guidewire systems for minimally invasive treatment of cerebrovascular conditions including stroke and brain aneurysms. The company's platform is designed to improve precision and consistency in complex vascular navigation and expand access to neurovascular intervention.
Context
- Company
- XCath
- Segment
- Surgical
- Event type
- Funding
- Geography
- Houston · United States